{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:54:01Z","timestamp":1747180441827,"version":"3.40.5"},"reference-count":30,"publisher":"Informa UK Limited","issue":"2-3","license":[{"start":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T00:00:00Z","timestamp":1588464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["HIV Research & Clinical Practice"],"published-print":{"date-parts":[[2020,5,3]]},"DOI":"10.1080\/25787489.2020.1794439","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T05:22:31Z","timestamp":1595827351000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-na\u00efve and treatment-experienced patients with human immunodeficiency virus-1 infection"],"prefix":"10.1080","volume":"21","author":[{"given":"Erkki","family":"Lathouwers","sequence":"first","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2469-8426","authenticated-orcid":false,"given":"Sareh","family":"Seyedkazemi","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghan","family":"Luo","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley","family":"Brown","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"De Meyer","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7958-2928","authenticated-orcid":false,"given":"Eric Y.","family":"Wong","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,7,26]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy463"},{"key":"e_1_3_3_3_1","volume-title":"HIV Drug Resistance Surveillance Guidance: 2015 Update (Technical Update)","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. HIV Drug Resistance Surveillance Guidance: 2015 Update (Technical Update). Geneva, Switzerland: WHO; 2015."},{"key":"e_1_3_3_4_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf. Accessed April 24 2019."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1889"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/427192"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2017.1387690"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2018.0100"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2314-2321.2005"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01184-07"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2012.01060.x"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000618"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-11-39"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328345ee95"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12211"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2012.00989.x"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12386"},{"key":"e_1_3_3_18_1","unstructured":"European AIDS Clinical Society. EACS Guidelines Version 10.0. November 2019. https:\/\/www.eacsociety.org\/files\/2018_guidelines-9.1-english.pdf. Accessed April 24 2020."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.8431"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001817"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002463"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1213"},{"issue":"1","key":"e_1_3_3_23_1","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","article-title":"EMERALD study group. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial","volume":"5","author":"Orkin C","year":"2018","unstructured":"Orkin C, Molina J-M, Negredo E, et\u00a0al. EMERALD study group. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5(1):e23\u2013e34.","journal-title":"Lancet HIV."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104543"},{"issue":"4","key":"e_1_3_3_25_1","first-page":"132","article-title":"Update of the drug resistance mutations in HIV-1","volume":"24","author":"Wensing AM","year":"2017","unstructured":"Wensing AM, Calvez V, G\u00fcnthard HF, et\u00a0al. 2017 Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2016;24(4):132\u2013141.","journal-title":"Top Antivir Med."},{"key":"e_1_3_3_26_1","unstructured":"PREZISTA \u00ae (darunavir) [package insert]. Titusville NJ: Janssen Therapeutics; September 2016."},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2007.0173"},{"key":"e_1_3_3_28_1","unstructured":"De Meyer S Dierynck I Lathouwers E et\u00a0al. Identification of mutations predictive of a diminished response to darunavir\/ritonavir (refined profile): analysis of data from treatment-experienced subjects in POWER 1 2 3 and DUET-1 and DUET-2. Presented at: 6th European HIV Drug Resistance Workshop; March 26\u201328 2008; Budapest Hungary. Abstract 54."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2014.0020"},{"key":"e_1_3_3_30_1","first-page":"175","article-title":"Profile of once-daily darunavir\/cobicistat fixed-dose combination for the treatment of HIV\/AIDS","volume":"8","author":"Navarro J","year":"2016","unstructured":"Navarro J, Curran A. Profile of once-daily darunavir\/cobicistat fixed-dose combination for the treatment of HIV\/AIDS. HIV AIDS (Auckl). 2016;8:175\u2013182.","journal-title":"HIV AIDS (Auckl)."},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-018-0238-8"}],"container-title":["HIV Research & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/25787489.2020.1794439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T15:00:21Z","timestamp":1717599621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/25787489.2020.1794439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,3]]},"references-count":30,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2020,5,3]]}},"alternative-id":["10.1080\/25787489.2020.1794439"],"URL":"https:\/\/doi.org\/10.1080\/25787489.2020.1794439","relation":{},"ISSN":["2578-7489","2578-7470"],"issn-type":[{"type":"print","value":"2578-7489"},{"type":"electronic","value":"2578-7470"}],"subject":[],"published":{"date-parts":[[2020,5,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhct21","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhct21","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}